List of Bioinformatics Companies in Maryland - 18

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time. APT’s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. APT’s technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank™ therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.

AsclepiX Therapeutics is focused on transforming the treatment of ocular diseases through the rapid clinical development of groundbreaking therapies aimed at empowering patients and their families around the world with the freedom to live their best lives. Using pioneering computational biology methods, we have identified multiple families of peptides that are potent regulators of vascular homeostasis. Our clinical candidates are derived from these peptides and work through naturally existing, highly evolved, and self-regulating mechanisms of homeostasis that maintain our health and well-being.

BiomX (NYSE America: PHGE) is developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

We help scientists solve disease, develop drugs, and extend healthspan by building tools that simplify R&D, simulate biology, and untangle the complexity of life. Streamline computational analysis today. Discover drugs tomorrow.

BullFrog AI (NASDAQ: BFRG) is a technology-enabled life science company using advanced artificial intelligence (AI) to usher in the next generation of lifesaving therapies. With our leading-edge platform, bfLEAP™, we aid in accelerating and de-risking drug discovery and clinical development using one of the industry's most advanced graph analytic AI technologies. The Problem: The drug development landscape is littered with failed products and unrealized ROI — all while patients are desperately waiting for treatments that often don't come: • The cost of bringing a drug to market is $.8 to $2.8 billion • Almost 90% of drugs don't get there • The average time to market is 8.5 YEARS Our Solution: We're applying machine learning and AI in drug development to identify new potential therapeutic targets, optimize clinical trials, rescue and repurpose drugs for new indications, and discover new drug targets. By identifying hidden relationships in clinical data, we aim to mitigate risk and elevate the trajectory of precision medicine. Our Technology: The bfLEAP™ platform delivers in a way that neural network models cannot: Explainable AI. We use network models in an interactive graph machine learning format to display and explain your data insights with confidence. Say goodbye to "black box" processing and say hello to AI outputs you can explore and understand. Join Us in Our Mission: With our platform's superior capabilities, a high-powered team of industry experts, and a pipeline of exclusive in-licensed assets for clinical development, BullFrog AI is pushing the boundaries of AI-assisted drug development. Make BullFrog AI an extension of your organization and clear your analytical barriers. Leap into the next generation of drug development with BullFrog AI.

CosmosID provides award-winning, end-to-end microbiome solutions. They offer NGS, Metabolomics, Bioinformatics, as well as the world's most advanced microbiome analysis software, CosmosID-HUB: Microbiome. The HUB relies on validated databases and algorithms specifically designed for maximum sensitivity, precision and lowest false positive rates. Unlike other solutions, CosmosID delivers strain-level results – we understand that the biologically informative and actionable unit in microbiology is not a genus or species, but ultimately a strain and its unique genetic and metabolic properties. CosmosID was founded in 2008 by Dr. Rita Colwell, former director of the National Science Foundation and currently Distinguished University Professor at the University of Maryland and Johns Hopkins University Bloomberg School of Public Health. To learn more please visit www.cosmosid.com.

"EzBiome, Inc. is a microbiome company promising the discovery of exciting new biology and transformative therapeutics through data- and database-driven microbial taxonomy, new bacterial species concept and standard, and the use of carefully curated and expert validated reference database that includes >3,000 new species. We cater world-class sample to discovery services on microbial identification, microbial genomics, microbiome bioinformatics, and database expertise for businesses worldwide for regulated and non-regulated applications to shorten the time for microbiota-based discovery and development of therapeutics and companion diagnostics for microbiome-related diseases."

The Food and Drug Administration is an agency within the Department of Health and Human Services. The FDA is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the safety of our nation's food supply, cosmetics, and products that emit radiation. FDA also has responsibility for regulating the manufacturing, marketing, and distribution of tobacco products to protect the public health and to reduce tobacco use by minors. FDA is responsible for advancing the public health by helping to speed innovations that make medical products more effective, safer, and more affordable and by helping the public get the accurate, science-based information they need to use medical products and foods to maintain and improve their health. FDA also plays a significant role in the Nation's counterterrorism capability. FDA fulfills this responsibility by ensuring the security of the food supply and by fostering development of medical products to respond to deliberate and naturally emerging public health threats.

Howard Hughes Medical Institute is a biomedical research organization focusing on advancing medical and life sciences research.

Infinity Bio is a technology company that provides detailed insights into the immune system using its proprietary antibody profiling platform. The company’s core technology comprehensively measures the antibody reactome, revealing the targets of individual immune responses against all known human viruses, human proteins (autoimmunity), and allergen proteins. Infinity's assay, MIPSA, was developed at Johns Hopkins University in Ben Larman's Lab of Precision Immunology. It builds off decades of work in the fields of genomics, proteomics, immunology, and bioinformatics. Our assay was engineered to enable best-in-class turnaround times and cost. With a team of experienced professionals and a state-of-the-art facility, we are poised to make a significant impact to research and for our customers.

Leidos is a Fortune 500® innovation company rapidly addressing the world’s most vexing challenges in national security and health. The company's global workforce of 48,000 collaborates to create smarter technology solutions for customers in heavily regulated industries. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $15.4 billion for the fiscal year ended December 29, 2023. Leidos was cited for the meaningful work employees perform that is challenging, impactful, and aligned with our customers’ missions as reasons professionals want to work and stay at our company. Leidos has also been named to lists including Forbes’ Best Employers for Diversity, Forbes’ America’s Best Employers for Women, Military Times Best for Vets Employers, and Ethisphere Institute’s World's Most Ethical Companies®. Employees enjoy career enrichment opportunities available through mobility and development and experience rewarding relationships with supportive supervisors and talented colleagues and customers. Employees appreciate our flexible work environment, allowing for and encouraging a true work-life balance. Our professionals are also excited about our Employee Resource Groups, like the Collaborative Outreach with Remote and Embedded Employees (CORE), which strives to create an environment where every employee, regardless of location, feels fully engaged as a valued employee of Leidos. Your most important work is ahead, visit careers.leidos.com for our latest opportunities.

Mission We harness the power of molecular microbiology to develop diagnostic solutions that will optimize the treatment of life-threatening, drug resistant infections. We seek to dramatically transform patient care to guide antibiotic therapy selection and help improve antibiotic stewardship. About Headquartered in Rockville, Maryland, OpGen (NASDAQ:OPGN) is a precision medicine company harnessing the power of molecular diagnostics to help combat infectious disease. Our innovative approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels to address the global threat of antimicrobial resistance (AMR), improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs). Together we improve patient care and fight AMR through cutting edge molecular microbiology.

Personal Genome Diagnostics (PGDx) is empowering the fight against cancer by unlocking actionable information from the genome. We are committed to developing a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide.Our expertise in advanced cancer genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. We specialize in high-throughput next-generation sequencing, proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive approaches in cancer.

Precision for Medicine is an industry-leading global clinical research services organization, purpose-built to improve the clinical research and development process for new therapeutics. Our novel approach integrates clinical operations excellence, with laboratory expertise, and advanced data sciences to inform every step. This maximizes our clients’ insight into patient biology, delivering more predictable trial outcomes and accelerating clinical development. We apply our expertise to trials at all stages—from early development through approval—with embedded experience in oncology and rare disease. With over 2000 dedicated professionals and 35 offices worldwide, we stand ready to help accelerate life-changing treatments anywhere around the globe.

Psomagen, Inc., formerly Macrogen Corp, delivers genomic sequencing services to the clinical, academic, and consumer markets. Psomagen's labs are US-based and CLIA and CAP certified. Not only is the company accredited to perform the highest quality Sanger sequencing, Next-Generation Sequencing and Microarray Gene Analysis, it is also networked with Macrogen's worldwide headquarters, stretching its capabilities and capacity across a diverse set of labs around the world. Learn more at psomagen.com.

Sapio Sciences' mission is to improve lives by accelerating discovery, and because science is complex, Sapio makes technology simple. Sapio is a global business offering an all-in-one science-aware (TM) lab informatics platform combining cloud-based LIMS, ELN, and Jarvis data solutions. Sapio serves some of the largest global and specialist brands, including biopharma, CRO/CDMOs and clinical diagnostic labs across NGS genomic sequencing, bioanalysis, bioprocessing, stability, clinical, histopathology, drug research, and in vivo studies. Customers love Sapio's platform because it is robust, scalable, and with no-code configuration, can quickly adapt to meet unique needs.

Developed a computational platform that converts recombinant proteins intomaterial-binding variants that can be used to coat implants, devices, and injectable carriers.

VERACHEM LLC is a biotechnology company based out of P.O. BOX 2206, GERMANTOWN, Maryland, United States.